mRCC: immediate nephrectomy shows no additional benefit in SURTIME

  • Bex A & al.
  • JAMA Oncol
  • 13 Dec 2018

  • curated by Deepa Koli
  • Univadis Clinical Summaries
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • In patients with clear cell metastatic renal cell carcinoma (mRCC), sunitinib followed by cytoreductive nephrectomy (CN) yields progression-free rate (PFR) and survival similar to immediate CN.
  • The deferred approach improved OS in the intent-to-treat (ITT) but not the per protocol (PP) population.

Why this matters

  • Sunitinib treatment before planned surgery may identify patients with inherent resistance to systemic therapy.

Study design

  • In the open-label SURTIME trial, 99 treatment-naive patients (vs 458 planned) with clear cell mRCC were randomly assigned to immediate CN followed by sunitinib (n=50) or sunitinib followed by CN (deferred group; n=49).
  • Revised endpoint: 28-week PFR.
  • Funding: Pfizer.

Key results

  • Median follow-up, 3.3 years.
  • 48 patients received presurgical sunitinib in the deferred group, whereas 40 received postoperative sunitinib in the immediate CN group.
  • ITT population: in the deferred CN vs the immediate CN groups:
    • 28-week PFR was 43% vs 42% (P=.61).
    • PFS was not statistically different (HR, 0.88; P=.57).
    • Median OS was significantly higher (32.4 vs 15.0 months; HR, 0.57; P=.03).
    • Grade ≥3 adverse event rate was 58% vs 52%.
  • In the PP population (n=73), OS was similar between both groups (HR, 0.71; P=.23).

Limitations

  • Early termination resulting from poor accrual.

Please confirm your acceptance

To gain full access to GPnotebook please confirm:

By submitting here you confirm that you have accepted Terms of Use and Privacy Policy of GPnotebook.

Submit